SAHA (suberoylanilide hydroxamic acid) is the first HDAC inhibitor approved by the FDA to treat refractory cutaneous T-cell lymphoma and has shown anticancer activity in several solid tumors including hematological malignancies [26, 27], NSCLC [28], and SCLC [29]. Here, HDAC9 is linked to small cell lung carcinoma.